Review Article

Comparative Study and Efficacy of Proton Pump Inhibitors in the Indian Pharmaceutical Landscape

Dawa Namgyal Bhutia*, Sandipan Chatterjee
Department of Pharmacology, Karnataka College of Pharmacy, Bengaluru-560064, India.
***Corresponding author's E-mail:** dawanamgyal21@gmail.com

Received: 22-03-2024; **Revised:** 18-05-2024; **Accepted:** 29-05-2024; **Published on:** 15-06-2024.

ABSTRACT

PPIs (proton pump inhibitors) are a group of strong molecules which are outstandingly used for the treatment of acidic diseases, such as GERD, peptic ulcers and functional dyspepsia. This research concentrated on the function of PPIs within the Indian market, especially their mechanism of action, the commonly prescribed patterns, and the pharmacoeconomic ones. The stomach produces acidic juice which helps the digestion process and deactivates the barns inside the food we take. Consequently, if acid secretion occurs at fast rate, a strong risk for acid-driven illnesses develops. Of the factors discussed above, Omeprazole, Pantoprazole, Esomeprazole, Lansoprazole, and Rabeprazole, the first among those is an all-known PPIs group, which efficiently suppresses the production of gastric acid and thus, occupies the first place among the drugs administered for gastrointestinal disorders in India. The study stresses the need for safe and reduced side effects Prescribing policy assessment and the monitoring of the PPI use to ensure appropriate prescribing and prevent over-use of these medicines. The study unveiled the surprising regulation of PPI prescription patterns and usage for managing acid-related diseases. The survey likewise highlighted interactions of PPIs with other drugs, which proves a very important aspect of monitoring as well as strictly prescribing practices. Nonetheless, some of the findings stem from the frequency and the variability of PPIs' use amongst patients and the potential prevention of conditions like Barrett's esophagus and ulcer recurrence. On the whole, this result highlighted that to have improved treatment outcomes as well as the quality of healthcare in the country, it is crucial to optimize PPI therapy. PPIs have a prominent role in the management of acid-generated diseases in the Indian healthcare system and the position of continuous work out trying to make patients get optimized outcomes and also to regulate healthcare resource utilization.

Keywords: Proton pump inhibitors, peptic ulcers, gastroesophageal reflux disease, functional dyspepsia, prescription pattern, Indian market.

INTRODUCTION

The human stomach secretes acidic fluid which is as low as pH 2 and it is the only organ to do so. In ingested foods the bacteria which is contained gets sterilized by such gastric secretion. The gastric secretion is also used for digestion and absorption of protein, calcium, vitamin B12etc, Various protective membranes is present such as muscle constriction at the junction of the stomach and oesophageal and mucosa mucus/bicarbonate output to avoid the acid from damaging the intestinal region. Sometimes as soon as the corrosive emission overcomes this protective membrane the gastrointestinal mucosa gets damaged and results in numerous acid-linked disease such as GERD or Gastroesophageal reflux disease, gastric abscess and functional dyspepsia[1].To overcome this disease proton pump inhibitors are the most potent medicine to suppress the production of gastric acid production[2]. For gastrointestinal disorders proton pump inhibitor stand the utmost prearranged drugs in the healthcare system[3]. Proton pump inhibitor are the course of medication that comprise Omeprazole, Pantoprazole, esomeprazole, lansoprazole, rabeprazole shown in Figure 1[4-5].

In the Canalicular membrane of the Oxyntic cell the Proton pump inhibitor targets the H^+,K^+-adenosine triphosphate (ATPase) and inhibit the secretion of gastric acid secretion[6,7]. Proton pump inhibitor has to be triggered so as to connect to the ATPase's CYSs, and the pace of activation differs based on the structures [8]. The enteric covering on proton pump inhibitors has been created to avoid the decomposition by stomach acid and to promote absorption in the slightly acidic environment of the small intestine. The combination of a pyridine ring and a benzimidazole ring through a sulfinyl bond generates the proton pump inhibitor structure[9]. The parietal cell's acidic environment gives sulfuryl ample energy, which it utilizes to chemically connect to the CYSs of the ATPase[8].The proton pump inhibitor is triggered when on either side of the sulfinyl group two proton gets attached to the nitrogen group[8-9]. By attaching to the cysteine molecule on the Adenosine Triphosphatase and creating a di-sulphide bond, the proton pump inhibitor deactivates the proton pump when it turns functional. Two pKa values of the PPIs impact the way they function[8,10-11]. The starting pKa, having a pH around 1.0, induces dissociation and deposits in the alkaline area of the Oxyntic cell canaliculus where acid is excreted. It ranges from 3.83 to 4.53. Among all the cells in the body, this one possesses the most acidic cytoplasm[11]. Approved medication has second pKa values ranging 0.11 and 0.79. The sulfinyl is reorganized into a charged sulfenic acid or a sulphonamide as a result of the second protonation on the benzimidazole. These elements

possess the energy to generate one or more ionic disulfide bonds with the cysteine sulfhydryls[10,12].

There are actually several different CYSs in the proton pump which the proton pump inhibitor may bind to[8,10]. The proton pump inhibitors bind to CYS813 on the proton transporter's acidic luminal side, inhibiting the proton transport mechanism. In addition to being easily accessible for inhibiting substances like cysteine and dithiothreitol, which may dissociate the PPI and restart the transporter enzyme and the region is also easily accessible to PPIs for binding[11].PPIs that activate more slowly, including pantoprazole and tenatoprazole, are interacted by the cysteine at position 822, located within the sixth membrane-spanning an area of the Adenosine Triphosphatase. As reducing chemicals can't easily access CYS822, the PPI's disulfide bonds completely block the proton pump[11]. For the PPI to undergo the above-described acidic activation, it must first reach the parietal cell's acidic site of action whereas the proton pump is still working properly. Only after that, the proton pump be deactivated. The PPI's pharmacokinetics—which start with inert absorption, distribution, breakdown by CYP P450 CYP3A4 or 2C19, and exclusion—determine the concentration at the site of action. The precise calculation of the metabolic rate can be challenging due to the simultaneous restrictions of development and genetics.



Figure 1: Structure of Proton Pump Inhibitors

Proton pump inhibitor in the Indian market

Pharmacoeconomics is an essential component of medical research in countries that are developing. The cost of medicines serves an important part in acceptable drug prescription rates and has an important influence on patient compliance with disease treatment. The pharmaceutical industry provides several branded varieties of the same drug at substantially varying costs. In India, the vast majority of drugs come in brands, most of which are also recommended by doctors. If the expensive brand is suggested, it could have an adverse financial effect on the patient, especially in cases of GIT difficulties that require a longer-term treatment[13-14]. Previous studies show that there is substantial variation in pricing among different brands of drugs.

Pantoprazole consists of the largest number of varieties out of the 1439 distinctive oral PPI brands that are accessible in India, alongside 515 (34.85%) brands. Omeprazole includes 398 (26.72%) varieties, rabeprazole includes 372 (24.92%) brands, Lansoprazole includes 91 (7.25%) brands, and Esomeprazole includes only 33 (2.26%) varieties readily available. Of the 275 distinct brands of injectables PPIs that are currently accessible in India, Pantoprazole has the maximum number of varieties (218, 78.98%), followed by Rabeprazole (37, 13.40%), Omeprazole (13, 4.71%), and Esomeprazole only 8 (2.89%)[14].

Esomeprazole is available in different dosage forms of 40 mg and 20 mg oral, and 40 mg injectable preparations, with 19, 15, and 6 brands readily accessible, proportionately. The dosage forms of rabeprazole include 20mg, 10 mg oral and 40 mg, 20 mg injectable, having 285, 20, 30, and 1 product available for individuals, respectively. There are a total of 14 and 49 brands of lansoprazole available in oral formulations of 15 and 30 mg, respectively. Pantoprazole is distributed via the 29, 418, and 2, 209 identities in oral and injectable formulations of 40 mg and 20 mg, respectively. There are a total of six and fifteen brands of ilaprozole available in oral formulations of 10 mg and 5 mg, respectively. Omeprazole has dosages of 20 mg, 10 mg, and 40 mg.

Ingested esomeprazole prices 17-45 INR with a price ratio of 2.64 for 20 mg and 24-67 rupees with a price ratio of 2.79 for 40 mg. Oral rabeprazole prices around 5 and 45 INR with a price ratio of 9, as well as between 9.50 and 87.5 rupees with a price ratio of 9.21. Ingested lansoprazole varies between 21.80 to 52.60 INR for 15 mg, with a price ratio of 2.41; for 30 mg, the price ratio varies between 41 to 82 INR. Oral pantoprazole prices 18.55–58 INR with a cost ratio of 3.13 for 20 mg as well as 13.33–99 INR with a price ratio of 7.43 for 40 mg. Oral ilaprazole varies around 31.65 and 54.50 INR for 5 mg and 66.40 and 96 INR for 10 mg, with a cost ratio of 1.45. Oral omeprazole prices 19.80–25.50 INR with a price ratio of 1.29 for 10 mg, 4-105 INR with a price ratio of 26.27 for 20 mg, or 38–86.28 INR with a price ratio of 26.25 for 40 mg. Oral Dex rabeprazole prices around 18 and 71 INR for 5 mg and 35 to 86 INR for 10 mg, with an overall price ratio of 2.46 shown in Table 1[15].

Table 1: Proton Pump Inhibitors with their formulations, total brands, doses, minimum cost, maximum cost, cost ratio, cost range, and mean cost.

Drugs and formulations	Total brands	Doses	Maximum Cost (INR)	Minimum Cost (INR)	Cost ratio	Cost range	Mean cost
Oral preparations							
Omeprazole	13	10mg	25.5	19.8	1.29	5.7	23.84
	229	20mg	105	4	26.26	101	37.70
	6	40mg	86.28	38	2.27	48.28	61.09
Lansoprazole	14	15mg	52.6	21.8	2.41	30.7	28.98
	49	30mg	82	41	2.00	41	45.39
Esomeprazole	15	20mg	45	17	2.64	28	28.98
	19	40mg	67	24	2.79	43	48.94
Pantoprazole	29	20mg	58	18.55	3.13	39.45	36.25
	418	40mg	99	13.33	7.43	85.67	76.47
Rabeprazole	20	10mg	45	5	9.00	40	23.13
	285	20mg	87.5	9.5	9.21	78	44.57
Injectable preparations							
Omeprazole	4	IV 40mg	43	23.25	1.85	19.75	30
Rabeprazole	30	IV 20mg	89	46	1.93	43	64.87
	1	IV 40mg	-	68.8	-	-	68.8
Esomeprazole	6	IV 40mg	95.70	63	1.52	32.7	80.83
Pantoprazole	2	IV 20mg	79.5	54.39	1.46	25.11	66.94
	209	IV 40mg	168	41	4.10	127	56.89

Table 2: Cost variation of Fixed Dose Combination of Proton Pump Inhibitors in Indian

Drugs and formulations	Total brands	Doses	Maximum cost (INR)	Minimum cost (INR)	Cost ratio	Cost range	Mean cost
Oral preparations							
Omeprazole	13	10mg	25.5	19.8	1.29	5.7	23.84
	229	20mg	105	4	26.26	101	37.70
	6	40mg	86.28	38	2.27	48.28	61.09
Lansoprazole	14	15mg	52.6	21.8	2.41	30.7	28.98
	49	30mg	82	41	2.00	41	45.39
Esomeprazole	15	20mg	45	17	2.64	28	28.98
	19	40mg	67	24	2.79	43	48.94
Pantoprazole	29	20mg	58	18.55	3.13	39.45	36.25
	418	40mg	99	13.33	7.43	85.67	76.47
Rabeprazole	20	10mg	45	5	9.00	40	23.13
	285	20mg	87.5	9.5	9.21	78	44.57
Injectable preparations							
Omeprazole	4	IV 40mg	43	23.25	1.85	19.75	30
Rabeprazole	30	IV 20mg	89	46	1.93	43	64.87
	1	IV 40mg	-	68.8	-	-	68.8
Esomeprazole	6	IV 40mg	95.70	63	1.52	32.7	80.83
Pantoprazole	2	IV 20mg	79.5	54.39	1.46	25.11	66.94
	209	IV 40mg	168	41	4.10	127	56.89

Proton pump inhibitor in a fixed blend of dose

"Any product consisting of any blend of a medication and a device or a biological substance and a device or a drug and a biological product or a medication, apparatus, and a biological product" according to the FDA defines it. 2 or additional combinations of medications in a single dose of administration collectively referred to as fixed-dose combinations, or FDCs[16]. The benefit they offer is greater effectiveness with fewer side effects[17]. Experts prefer to implement this more often since it enhances patients' adherence to their prescribed medication regimes[18]. Enhanced conformity is one of the utmost vital aspects that impact a doctor's medication selection, especially when it comes to chronic medical conditions. In addition, when compared with taking separate medicines, FDCs aid in lowering the overall price of therapy. The target population, market share, and competition throughout brands of the same composition that exist in the market all contribute to the considerable variances in prices between them. Patients might be less likely to comply with these drugs as recommended if the increased cost increases their financial strain. According to a Technavio evaluation, the PPI medication market is expected to expand at an average rate of 4.17% by 2020 and achieve an estimated worth of $10.25 billion by 2025. Altogether this underwrites the worth difference among numerous PPI varieties when combined with other prescription drugs shown in Table 2[19].

Proton pump inhibitor: prescription and utilization

The US FDA and the SFDA or Saudi Food and Drug Authority have approved PPIs, including omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole, aimed at the management of common acid-associated conditions in adults[20]. This kind of medicine happens to be the most frequently prescribed medicine[21-26]. GERD or Gastrointestinal reflux disease, gastric abscess disease, corrosive and ulcerative esophagitis, and H. pylori contamination are just some of the disorders in which PPI medications are allowed[20]. The amount of time of treatment for proton pump inhibitors is generally short (2–8 weeks)[20,27]. International studies carried out in the past found that Proton pump inhibitors were excessively prescribed to people with polypharmacy, generally for a longer duration of time and deprived of an adequate indication[21-26].

The prolonged use of Proton pump inhibitors has been related to negative health consequences like lack of magnesium diarrhea caused by Clostridium difficile (C. difficile) infections, a condition known as vitamin B12 deficiency, respiratory infections, and dementia that looks despite their effectiveness and clinical important profile[20,28].

Monitoring prescriptions from patients for PPIs and analyzing their use according to recommended guidelines for indications and medication periods is important. Additionally, it has been found that PPIs can interact with antidepressant medications anticoagulants, and anticonvulsants that are all regularly prescribed, such as medications called phenytoin, escitalopram, clopidogrel, warfarin, and gliclazide, affecting the levels in the blood of these medications[29-31].

Investigation suggests that more than fifty percent of the medications given or distributed internationally are improperly handled, and fifty percent of patients fail to take them as recommended. In developed countries, ten percent to twenty percent of the national health budget is dedicated to drugs, but in underdeveloped nations, this percentage varies between twenty percent to forty percent[32-33]. Consequently, the overuse of medicines is a highly important matter requiring treatment[34]. Notwithstanding the reality that PPIs have remained to be improperly utilized, the wrong prescribing pattern for these medications is rising. Adverse reactions to drugs and drug-drug interactions are strongly associated with this.

Drug usage studies are structured, constant treatments that examine the appropriate consumption of medications based on established standards. These dynamic audit systems strive to gauge, identify, and document any suspected wrong prescription behavior in order to enhance the quality of drug consumption in hospitals. To maximize the advantages of medication therapy, actions with providers or patients will be needed if therapy turns out to be inappropriate[34].

By collecting data on medication practice, plus incidence, way of direction, dosage form, length of action, signs, and continuing after release, prescription patterns for PPIs were investigated[35]. With a men-to-women proportion of 1.13:1, 183 (53.06% out of the 343 patients examined) were men while 161 (46.94%) were women. There were a total of 27 individuals in the age categories of 40–50 (n = 64, i.e., 18.37%), between the ages of (n = 58, i.e., 16.91%), then 50–60 (n = 68, i.e., 19.53%), which constituted the majority of our patients. 7.88% of those being treated were aged less than 70[34].

In postoperative premises, co-prescription of PPIs with NSAIDS to stop NSAID-induced abscess (n =115, 33.24%) or steroids (n =25, 7%) was the most common reason for PPI application. Further symptoms and signs include pancreas inflammation a condition called gastric abscess ailment, and rupture of the gastric abscess. Several medications have been given in tandem with PPIs. The most often prescribed medicines are antimicrobial agents (n=205, 25.09%), minerals and vitamins (n=193, 23.62%), and analgesics (n=225, 27.54%)[35]. Rifampicin + Pantoprazole contributed to the majority of interactions between drugs, while Cefpodoxime + Pantoprazole ranked second. Pantoprazole (50.15%) was the most frequently prescribed drug among 342 individuals, which was followed by Rabeprazole (34.24%), Omeprazole (12.08%), and Esomeprazole (5.44%)[34].

Of all 342 individuals, 182 (53.35%) obtained a prescription for between four and seven drugs, 101 (29.71%) obtained a prescription for all three or fewer medicines, and 57 (8.13%)

obtained a prescription for a total of a total of seven medications. 250 (73.18%) of the 342 medications were categorized as "most suitable," and 91 (26.82%) as "suitable." Not a single medication was missing from the order. Out of 341 people, just 31 (9%) had an upper gastrointestinal (GI) endoscopy before a PPI prescription[34].

ADVERSE EFFECT OF PROTON PUMP INHIBITOR

PPIs are effectively and safely indicated for a variety of conditions with an extensive body of literature backing treatment. PPIs, on the other hand, have to be used continuously by patients who have gastroesophageal reflux disorder. These medicines are usually prescribed at high dosages for up to several months[35].

In the years 2010 and 2011, the Food and Drug Administration issued security guidance concerning a possible elevated danger of breakages related to osteoporosis and a lack of magnesium respectively[36-37]. Given PPIs' widespread usage, concerns about ADRs, or adverse drug reactions, have increased on an international level. Constipation, nausea, diarrhea, nausea, and stomach discomfort are the greatest common adverse reactions of PPIs. The previously mentioned negative consequences are controllable and fade away once the drug is discontinued. Furthermore, shortages of nutrients (iron, magnesium, and vitamin B12), back acid production, osteoporotic fractures, acute as well as ongoing interstitial nephritis (IN), chronic kidney disease, illnesses (clostridium difficile and respiratory infections), condition called anemia, and thrombocytopenia are some of the rare but serious adverse reactions resulting from a long-term PPI use[36-39].

Infections

Based on recent studies, prolonged Proton pump inhibitors users had a larger incidence of Clostridium difficile-associated diarrhea and pneumonia acquired in the community compared to non-PPI users. Individuals using PPIs have a higher total menace of respiratory infection, according to a thorough analysis of eight study designs (CI 1.11–1.46 OR 1.27; 95%)[40]. Altogether stacked case-control research indicated a rise in the likelihood of PPI application being connected with community-acquired pneumonia (CI 1.12–1.65OR 1.36; 95%) [41]. Nevertheless, a review of the literature including 4,141,634 unaffected by and 96,870 affected PPI individuals exhibited that Proton pump inhibitors were not related to a higher likelihood of respiratory infection acquired in the community[42]. Therefore, additional study remains required to fully comprehend the relationship between PPIs and pneumonia as well. Clostridium difficile infection (CDI), a significant cause of nosocomial diarrhea with an elevated likelihood of mortality and morbidity, is another illness associated with PPI medicine. Research which includes 136 people (19% obtained in the community; 81% acquired in the hospital setting) showed that continued use of PPIs is one of the main jeopardy factors for infections[43]. It is nevertheless unclear whether PPIs raise the risk of pneumonia and Clostridium difficile infection. The likelihood of bacterial goal in the stomach and esophagus is increased by overgrowing bacteria, that is one hypothesis put up to clarify this possible adverse repercussions. There is a need for additional clinical and mechanical inquiries on the link between infections and PPIs.

Cardiac adverse effect

PPI is one of the vital medications used following surgical procedures on the heart to stop upper intestinal hemorrhaging. Studies carried out in vitro on cardiomyocytes and muscle strips exhibited that PPIs may have undesirable inotropic effects[44-45]. The myocardium of both humans and rabbits produces gastrointestinal H+/K-ATPase; however, in an in vitro inquiry, pantoprazole did not affect the pH within the cell. On the opposite hand, pantoprazole might decrease heart contractility in vitro by decreasing myofilament activity and the Ca2 signal. This could be among the reasons underlying the adverse inotropic impacts caused by PPIs. Another alternative cause could be that PPIs hinder dimethylarginine dimethylaminohydrolase (DDAH) from completing its job, which is what eliminates 80% of asymmetric dimethylarginine (ADMA). By a recent preclinical examination, PPIs raised ADMA levels by 20–30% in mice and human endothelium cells[46]. ADMA suppresses natural killer cells by boosting blood vessel obstruction which promotes thrombosis and irritation. Considering the widespread use of this drug, additional study is needed to discover scientific proof of the harmful inotropic impacts of PPIs in animals.

ADVANTAGES OF PPIS

Proton pump inhibitors effectively avoid each expulsion of acid from the stomach, especially after the day following a daily, single-dose morning medical care. During the initial three to five days following the beginning of medication, the quantity of acid suppression that is taken by mouth progressively rises, despite being utilized for a longer amount of time, PPIs show no tolerance issues. Before breakfast intra-gastrin content which is tested in the morning does not show an important rise because overnight acid suppression is less effective and intra-gastric pH all through the nighttime remains around 2 in the mainstream of directed scenarios. PPIs having these characteristics may be helpful in lasting regulators of acid in the stomach excretion. Aspirin or NSAID medication requires long-term inhibition of acid production in the stomach to cure GERD and prevent the formation of gastroduodenal ulcers[47-51]. Patients with dysfunctional dyspepsia (FD) receive treatment for dyspepsia with acid-inhibiting agents, which are given intermittently or as required, but not continuously. Consequently, the demand for long-term PPI care comes from the following two primary considerations: GERD ongoing treatment and avoiding drug-related ulcer recurrence. Because gastroesophageal reflux disease usually happens during the postoperative phase, patients with GERD usually complain of symptoms of reflux after food. PPIs are beneficial for avoiding the return of symptoms of reflux and esophagus

erosions/ulcers since their extremely strong acid-reducing influence persists throughout the day[47-49]. Reappearance of GERD without ongoing treatment for a year has been estimated to be less than 15% during their continuous treatment, nevertheless, reappearance without maintenance therapy within a year is projected to be greater than 50%[52-53]. When PPIs or the H2RAs were investigated for their capacity to prevent GERD repetition, PPIs were found to be much more effective. Their use over time can additionally prevent Barrett's esophagus from progressing into dysplastic Barrett's esophagus, including adenocarcinomas. The efficacy of PPIs in treating Barrett's esophagus dysplastic changes is not completely proven. Though certain studies suggest that these drugs effectively avoid dysplastic changes, no evidence suggests that they exacerbate dysplastic changes[54].

As a consequence, long-term ongoing therapy with a PPI could prevent Barrett's cancer of the oesophageal from developing and is useful in preventing GERD recurrence. Long-term PPI therapy is better than H2RAs in preventing a recurrence of aspirin-induced gastroduodenal ulcers, decreasing recurrence to approximately ten percent of what was seen in those receiving placebo treatment[51,55-57]. PPIs were additionally demonstrated to cut the reappearance threat to a tenth part of the control collection in cases wherein an NSAID was administered all through the duration of a six- to twelve-month tracking period[56]. Although aspirin is frequently prescribed as an anti-thrombotic medicine among people with cerebrovascular or cardiovascular diseases, preventing aspirin-induced ulcers is crucial for reducing NSAID-induced ulcers. As a consequence, PPIs are the first-choice medicines used for avoiding ulcer recurrence associated with aspirin/NSAID usage. They are additionally extremely efficient and potent when used persistently for treating GERD and preventing recurrent infections.

PHARMACOKINETICS OF PROTON PUMP INHIBITOR

The discrepancies in the duration that every PPI suppresses acid in the stomach results may be triggered, at least in part, by the differences in cysteine binding. Current PPIs based on benzimidazole have half-lives of 1-2 hours which are equivalent[59-61]. However, the duration of impact surpasses what anyone could have anticipated based merely on the blood plasma half-life. The half-life of the H+ K+ -ATPase (about 54 hrs) suggests that the decrease of the production of stomach acid by PPIs continues for a longer period, though this is not necessarily the case because of the possible uncertainty of covalent connection to the proton pump. In human beings, the half-life for omeprazole, pantoprazole, as well as lansoprazole fluctuate between a little over fifteen hours to approximately 28 hours and 46 hours, correspondingly, for the recovery of acid in the stomach secretion[61-63]. The turnover of proteins, the initiation of indolent pumps, and the recurrence of subdued pump particles by naturally occurring reductant that disrupts the covalent connection among the Proton pump inhibitors and the pump permitting PPI disengagement are the variables that influence the rate of recovery of the emission of stomach acid after PPI inhibition. However, the development of a new, operating pump protein might be the sole variable in recovering acid secretion in the circumstance of PPIs that predicament to cysteine 822, which is unreachable and immune to reductant[61,64]. As a consequence, PPIs providing prolonged suppression of acid production are the ones that bind to cysteine 822 and accumulate and activate slowly. This could impact their treatment result, offering improved and permanent control of acid in their stomach secretion throughout the night hours.

It typically takes proton pump inhibitors a minimum of three days to achieve the maximal decrease in acid in the stomach resulting in a steady-state approach[65]. PPIs display a delayed starting impact due to the continuous activation and accumulation of PPI in the Oxyntic cell, in addition to the medication that is rapidly metabolized and eliminated from the body and the uninterrupted transition of passive stomach acid pumps to the lively state[63,66]. Only dynamically releasing pump particles at the exterior of the Oxyntic cell's secretory duct are prone to inhibition by a PPI; however, newly produced or activated pumps that are stimulated after the PPI's serum level collapses below the threshold will not be inhibited, whereas any pumps with covalently bound proton pump inhibitor will remain dormant up until suppression is overturned by a cellular reductant such as glutathione. Consequently, expanding the half-life of PPIs is an objective that should be obvious because a brief plasma duration allows for the quick renovation of stomach acid excretion by abandoned, reestablished, or original pumps; a longer PPI half-life will probably result in additional extended obstruction of proton pumps and is therefore probable to trigger better conquest of stomach acid secretion[63]. Selecting the enantiomeric form of a medication that is expected to have a slower metabolism has been one method of dealing with this (esomeprazole; S-omeprazole)[63,67]. However, there is no evidence that, when utilized at equivalent dosages, esomeprazole has any medicinal benefits over omeprazole[68]. Tenatoprazole, an imidazopyridine PPI, takes an average half-life of 7 hr, which is considered to be the longer period that of PPIs based on benzimidazole[69-70]. This indicates that tenatoprazole has a potential advantage over PPIs built on benzimidazole due to its extended duration of action, particularly when it comes to acid management at nighttime.

CONCLUSION

Finally, Proton pump inhibitors during the study of the Indian market is understanding the significance of such medicines that they can decrease gastric acid release and treat acid-linked ailments such as GERD, intestinal abscess and functional dyspepsia, PPIs such as Omeprazole, Pantoprazole, Esomeprazole, Lansoprazole, and Rabeprazole remain the most prescribed drug due to their extremely strong repressive result on acid production and the superior effectiveness of this drugs in treating the

gastrointestinal ailment. There should be strict monitoring of the offering or use of PPIs according to the recommended guidelines to minimize any inappropriate use without any interactions between drugs. The excessive prescribing of PPIs and additional medicines is a cause for specific warnings that need to be acted upon so that patients receive the best outcomes and healthcare resource utilization stays optimal. Besides more detailed research and economics studies conducted on proton pump inhibitors in India, we can also use the financial range and benefits of using mixed doses. The ability to comprehend the mode of action as well as to prolong the half-life of positive PPIs are important clauses towards upgrading the effectiveness of the acerbic secretion inhibition and the outcome of treatment. Thus, the study confirms the significance of medication in managing acid-related diseases as well as the requirement of regulating medical use, following up the medications, and implementing new research to improve the treatment capacity of medicine in India.

ACKNOWLEDGMENT

The author extends gratitude to the Department of Pharmacology, Karnataka College of Pharmacy, Bengaluru for providing the facilities.

Source of Support: The author(s) received no financial support for the research, authorship, and/or publication of this article

Conflict of Interest: The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

REFERENCES

1. Komazawa Y, Adachi K, Mihara T, Ono M, Kawamura A, Fujishiro H, et al. Tolerance to famotidine and ranitidine treatment after 14 days of administration in healthy subjects without Helicobacter pylori infection. J Gastroenterol Hepatol. 2003;18(6):678–82. DOI: http://dx.doi.org/10.1046/j.1440-1746.2003.03041.x
2. Bethesda. Liver Tox: Clinical and Research Information on Drug-Induced Liver Injury. National Institute of Diabetes and Digestive and Kidney Diseases. 2012. PMID: 31643176.
3. Heidelbaugh JJ, Kim AH, Chang R, Walker PC. Overutilization of proton-pump inhibitors: what the clinician needs to know Therapeutic advances in gastroenterology. 2012;5:219–32.
4. Shanika LGT, Reynolds A, Pattison S, Braund R. Proton pump inhibitor use: systematic review of global trends and practices. Eur J Clin Pharmacol. 2023;79(9):1159–72. DOI: http://dx.doi.org/10.1007/s00228-023-03534-z
5. Ratcliffe EG, Jankowski JA. Gastroesophageal reflux disease and Barrett oesophagus: an overview of evidence-based guidelines. Pol Arch Intern Med. 2019;129(7–8):516–25.
6. Sachs G. Proton pump inhibitors and acid-related diseases. Pharmacotherapy. 1997;17(1):22–37. DOI: http://dx.doi.org/10.1002/j.1875-9114.1997.tb03675.x
7. Sachs G, Shin JM, Briving C, Wallmark B, Hersey S. The pharmacology of the gastric acid pump: the H+, K+ ATPase. Annual Review of Pharmacology and Toxicology. 1995;35(1):277–305.
8. Roche VF. The chemically elegant proton pump inhibitors. Am J Pharm Educ. 2006;70(5):101. DOI: http://dx.doi.org/10.5688/aj7005101
9. Kaplan JH, Biochemistry of Na K-A. Annual review of biochemistry. 2002;71:511–35.
10. Litalien C, Th??or??t Y, Faure C. Pharmacokinetics of proton pump inhibitors in children. Clin Pharmacokinet. 2005;44(5):441–66. DOI: http://dx.doi.org/10.2165/00003088-200544050-00001
11. Sachs G, Shin JM, Howden CW. Review article: the clinical pharmacology of proton pump inhibitors. Aliment Pharmacol Ther . 2006;23 Suppl 2(s2):2–8. DOI: http://dx.doi.org/10.1111/j.1365-2036.2006.02943.x
12. Gibbons TE, Gold BD. The use of proton pump inhibitors in children: a comprehensive review. Paediatr Drugs. 2003;5(1):25–40.
13. Barkun A, Leontiadis G. Systematic review of the symptom burden, quality of life impairment and costs associated with peptic ulcer disease. Am J Med. 2010;123(4):358-66.e2. DOI: http://dx.doi.org/10.1016/j.amjmed.2009.09.031
14. Deolekar P, Dongerkery K, Yadav P, Sonawane J. Pharmacoeconomic analysis of Oral & Injectable Proton Pump Inhibitors available in India. J Pharmacoeconomics Pharm Manag. 2023; DOI: http://dx.doi.org/10.18502/jppm.v9i2.13369
15. Bargade M, Mahatme M, Hiware S, Admane P. Cost-minimization analysis of proton pump inhibitors in India. Int J Basic Clin Pharmacol . 2016;1043–7. DOI: http://dx.doi.org/10.18203/2319-2003.ijbcp20161566
16. Gautam CS, Saha L. Fixed dose drug combinations (FDCs): rational or irrational: a view point. Br J Clin Pharmacol. 2008;65(5):795–6. DOI: http://dx.doi.org/10.1111/j.1365-2125.2007.03089.x
17. Marakhouski KY, Karaseva GA, Ulasivich DN, Marakhouski YK. Omeprazoledomperidone fixed dose combination vs omeprazole monotherapy: a phase 4, open-label, comparative, parallel randomized controlled study in mild to moderate gastroesophageal reflux disease. Clinical Medicine Insights: Gastroenterology. 2017;10.
18. Bangalore S, Kamalakkannan G, Parkar S, Messerli FH. Fixed-dose combinations improve medication compliance: a meta-analysis. Am J Med. 2007;120(8):713–9. DOI: http://dx.doi.org/10.1016/j.amjmed.2006.08.033
19. Deolekar P, Vivek K, Ghosh S, Naseem A, Srivathsan M, Rai VS, et al. Pharmacoeconomic analysis of fixed-dose combinations of proton pump inhibitors available in India. Cureus. 2023;15(3):e36112. DOI: http://dx.doi.org/10.7759/cureus.36112
20. Algabbani AM, Alangari AS. Proton pump inhibitor prescribing patterns and utilization: A retrospective chart review analysis. Saudi Pharm J. 2023;31(12):101841-6. DOI: http://dx.doi.org/10.1016/j.jsps.2023.101841
21. Forgacs I, Loganayagam A. Overprescribing proton pump inhibitors. BMJ. 2008;336(7634):2–3. DOI: http://dx.doi.org/10.1136/bmj.39406.449456.BE
22. Jarchow-Macdonald AA, Mangoni AA. Prescribing patterns of proton pump inhibitors in older hospitalized patients in a Scottish health board. Geriatrics & gerontology international. 2013;13(4):1002–9.
23. Schepisi R, Fusco S, Sganga F, Falcone B, Vetrano DL, Abbatecola A, et al. Inappropriate use of proton pump inhibitors in elderly patients discharged from acute care hospitals. J Nutr Health Aging . 2016;20(6):665–70. DOI: http://dx.doi.org/10.1007/s12603-015-0642-5
24. Alhossan A, Alrabiah Z, Alghadeer S, Bablghaith S, Wajid S, Al-Arifi M. Attitude and knowledge of Saudi community pharmacists towards use of proton pump inhibitors. Saudi Pharm J. 2019;27(2):225–8. DOI: http://dx.doi.org/10.1016/j.jsps.2018.11.002

25. Madi L, Ahmed Elhada AH, Alrawashdeh H, Ahmed A. Prescribing pattern of proton pump inhibitors in Qatar Rehabilitation Institute: A retrospective study. J Res Pharm Pract. 2019;8(2):101–4. DOI: http://dx.doi.org/10.4103/jrpp.JRPP_18_79

26. Al-Dosari BS, Binafeef BM, Alsolami SA. Prescribing pattern of proton pump inhibitors among patients admitted to medical ward at King Abdulaziz University Hospital, Jeddah, Saudi Arabia: A retrospective study: A retrospective study. Saudi Med J. 2021;42(12):1313–9. DOI: http://dx.doi.org/10.15537/smj.2021.42.12.20210488

27. Haastrup PF, Jarbøl DE, Thompson W, Hansen JM, Søndergaard J, Rasmussen S. When does proton pump inhibitor treatment become long term? A scoping review. BMJ Open Gastroenterol . 2021;8(1):55-62. DOI: http://dx.doi.org/10.1136/bmjgast-2020-000563

28. Wan A, Halpape K, Talkhi SC, Dixon C, Dossa H, Tabamo J, et al. Evaluation of prescribing appropriateness and initiatives to improve prescribing of proton pump inhibitors at Vancouver General Hospital. Can J Hosp Pharm. 2018;71(5):308–15. DOI: http://dx.doi.org/10.4212/cjhp.v71i5.2841

29. Jungnickel PW. Pantoprazole: a new proton pump inhibitor. Clin Ther. 2000;22(11):1268–93.DOI: http://dx.doi.org/10.1016/s0149-2918(00)83025-8

30. Wedemeyer R-S, Blume H. Pharmacokinetic drug interaction profiles of proton pump inhibitors: an update. Drug Saf . 2014;37(4):201–11. DOI: http://dx.doi.org/10.1007/s40264-014-0144-0

31. Aljadani R, Aseeri M. Prevalence of drug–drug interactions in geriatric patients at an ambulatory care pharmacy in a tertiary care teaching hospital. BMC Res Notes. 2018;11(1). DOI: http://dx.doi.org/10.1186/s13104-018-3342-5

32. World Health Organization. WHO Policy perspectives on medicines. Geneva. 2002;1.

33. Kujur AD, Ekka NM. A Study on the Prescribing Pattern of Proton Pump Inhibitors in the General Surgery Wards of Premier Medical Institute in Eastern India. IOSR Journal of Dental and Medical Sciences. 2020;19:16–20.

34. Ke Y-L, Hsieh H-H, Wu T-Y, Lin Y-T, Chen C-H. Evaluation of levofloxacin utilization rationality by computerized physician order entry system. J Microbiol Immunol Infect. 2015;48(2):S50. DOI: http://dx.doi.org/10.1016/j.jmii.2015.02.096

35. Raghunath AS, O'Morain C, McLoughlin RC. Review article: the long-term use of proton-pump inhibitors. Aliment Pharmacol Ther . 2005;22 Suppl 1(s1):55–63.DOI: http://dx.doi.org/10.1111/j.1365-2036.2005.02611.x

36. Schoenfeld AJ, Grady D. Adverse effects associated with proton pump inhibitors. JAMA Intern Med. 2016;176(2):172–4. DOI:http://dx.doi.org/10.1001/jamainternmed.2015.7927

37. Wilhelm SM, Rjater RG, Kale-Pradhan PB. Perils and pitfalls of long-term effects of proton pump inhibitors. Expert Rev Clin Pharmacol . 2013;6(4):443–51. DOI: http://dx.doi.org/10.1586/17512433.2013.811206

38. Parikh N, Howden CW. The safety of drugs used in acid-related disorders and functional gastrointestinal disorders. Gastroenterol Clin North Am. 2010;39(3):529–42. DOI: http://dx.doi.org/10.1016/j.gtc.2010.08.009

39. Abraham NS. Proton pump inhibitors: potential adverse effects. Curr Opin Gastroenterol. 2012;28(6):615–20. DOI: http://dx.doi.org/10.1097/MOG.0b013e328358d5b9

40. Eom C-S, Jeon CY, Lim J-W, Cho E-G, Park SM, Lee K-S. Use of acid-suppressive drugs and risk of pneumonia: a systematic review and meta-analysis. CMAJ. 2011;183(3):310–9. DOI: http://dx.doi.org/10.1503/cmaj.092129

41. Johnstone J, Nerenberg K, Loeb M. Meta-analysis: proton pump inhibitor use and the risk of community-acquired pneumonia: META-ANALYSIS: PPI USE AND COMMUNITY-ACQUIRED PNEUMONIA. Aliment Pharmacol Ther . 2010;31(11):1165–77. DOI: http://dx.doi.org/10.1111/j.1365-2036.2010.04284.x

42. Filion KB, Chateau D, Targownik LE, Durand GA, Tamim M, Teare H, et al. Proton pump inhibitors and the risk of hospitalisation for community-acquired pneumonia: replicated cohort studies with metaanalysis. Gut. 2014;63(4):552–8.

43. Ogielska M, Lanotte P, Le Brun C, Valentin AS, Garot D, Tellier A-C, et al. Emergence of community-acquired Clostridium difficile infection: the experience of a French hospital and review of the literature. Int J Infect Dis. 2015;37:36–41. DOI: http://dx.doi.org/10.1016/j.ijid.2015.06.007

44. Schillinger W, Teucher N, Sossalla S, Kettlewell S, Werner C, Raddatz D, et al. Negative inotropy of the gastric proton pump inhibitor pantoprazole in myocardium from humans and rabbits: evaluation of mechanisms: Evaluation of mechanisms. Circulation. 2007;116(1):57–66. DOI: http://dx.doi.org/10.1161/CIRCULATIONAHA.106.666008

45. Sossalla S, Schotola H, Schmitto J, Toischer K, Sohns C, Schwörer H, et al. Effects of different proton pump inhibitors on cardiac contractility in isolated human failing myocardium. J Cardiovasc Surg (Torino). 2011;52(3):437–44.

46. Shah NH, LePendu P, Bauer-Mehren A, Ghebremariam YT, Iyer SV, Marcus J, et al. Proton pump inhibitor usage and the risk of myocardial infarction in the general population. PLoS One. 2015;10(6):e0124653. DOI: http://dx.doi.org/10.1371/journal.pone.0124653

47. Hongo M, Fujimoto K. Gastric Polyps Study Group. Incidence and risk factor of fundic gland polyp and hyperplastic polyp in long-term proton pump inhibitor therapy: a prospective study in Japan. Journal of gastroenterology. 2010;45:618–24.

48. Labenz J, Armstrong D, Lauritsen K, Katelaris P, Schmidt S, Schütze K, et al. Esomeprazole 20 mg vs. pantoprazole 20 mg for maintenance therapy of healed erosive oesophagitis: results from the EXPO study 1. Alimentary pharmacology & therapeutics. 2005;22(9):803–11.

49. Kinoshita Y, Kato M, Fujishiro M, Masuyama H, Nakata R, Abe H, et al. Efficacy and safety of twice-daily rabeprazole maintenance therapy for patients with reflux esophagitis refractory to standard once-daily proton pump inhibitor: the Japan-based EXTEND study. J Gastroenterol. 2018;53(7):834–44. DOI: http://dx.doi.org/10.1007/s00535-017-1417-z

50. Sugano K, Choi MG, Lin JT, Goto S, Okada Y, Kinoshita Y, et al. Multinational, double-blind, randomised, placebo-controlled, 15 prospective study of esomeprazole in the prevention of recurrent peptic ulcer in low-dose acetylsalicylic acid users: the LAVENDER study. Gut. 2014;63(7):1061–8.

51. Sugano K, Kinoshita Y, Miwa H, Takeuchi T. Esomeprazole NSAID Preventive Study Group. Randomised clinical trial: esomeprazole for the prevention of nonsteroidal anti- inflammatory drug-related peptic ulcers in J apanese patients. Alimentary pharmacology & therapeutics. 2012;36(2):115–25.

52. Pace F, Annese V, Prada A, Zambelli A, Casalini S, Nardini P, et al. Italian Rabeprazole Study Group. Rabeprazole is equivalent to omeprazole in the treatment of erosive gastro-oesophageal reflux disease: a randomised, double-blind, comparative study of rabeprazole and omeprazole 20 mg in acute treatment of reflux oesophagitis, followed by a maintenance open-label, low-dose therapy with rabeprazole. Digestive and liver disease. 2005;37:741–50.

53. Lundell LR, Dent J, Bennett JR, Blum AL, Armstrong D, Galmiche JP, et al. Endoscopic assessment of oesophagitis: clinical and functional correlates and further validation of the Los Angeles classification. Gut. 1999;45(2):172–80.

DOI: http://dx.doi.org/10.1136/gut.45.2.172

54. Singh S, Garg SK, Singh PP, Iyer PG, El-Serag HB. Acid-suppressive medications and risk of oesophageal adenocarcinoma in patients with Barrett's esophagus: a systematic review and meta-analysis. Gut. 2014;63(8):1229–37. DOI: http://dx.doi.org/10.1136/gutjnl-2013-305997

55. Hawkey CJ, Karrasch JA, Szczepański L, Walker DG, Barkun A, Swannell AJ, et al. Omeprazole compared with misoprostol for ulcers associated with nonsteroidal antiinflammatory drugs. N Engl J Med. 1998;338(11):727–34.
DOI: http://dx.doi.org/10.1056/nejm199803123381105

56. Yeomans ND, Tulassay Z, Juhász L, Rácz I, Howard JM, van Rensburg CJ, et al. A comparison of omeprazole with ranitidine for ulcers associated with nonsteroidal antiinflammatory drugs. Acid Suppression Trial: Ranitidine versus Omeprazole for NSAID-associated Ulcer Treatment (ASTRONAUT) Study Group. N Engl J Med [Internet]. 1998;338(11):719–26.
DOI: http://dx.doi.org/10.1056/NEJM199803123381104

57. Sugano K, Kontani T, Katsuo S, Takei Y, Sakaki N, Ashida K, et al. Lansoprazole for secondary prevention of gastric or duodenal ulcers associated with long-term non-steroidal anti-inflammatory drug (NSAID) therapy: results of a prospective, multicenter, double-blind, randomized, double-dummy, active controlled trial. Journal of gastroenterology. 2012;47:540–52.

58. Gerloff J, Mignot A, Barth H, Heintze K. Pharmacokinetics and absolute bioavailability of lansoprazole. Eur J Clin Pharmacol. 1996;50(4):293–7. DOI: http://dx.doi.org/10.1007/s002280050111

59. Radhofer-Welte S. Pharmacokinetics and metabolism of the proton pump inhibitor pantoprazole in man. Drugs Today (Barc). 1999;35(10):765–72.
DOI: http://dx.doi.org/10.1358/dot.1999.35.10.561695

60. Fuhr U, Jetter A. Rabeprazole: pharmacokinetics and pharmacokinetic drug interactions. Pharmazie. 2002;57(9):595–601.

61. Shin JM, Sachs G. Restoration of acid secretion following treatment with proton pump inhibitors. Gastroenterology. 2002;123(5):1588–97. DOI: http://dx.doi.org/10.1053/gast.2002.36593

62. Katashima M, Yamamoto K, Tokuma Y, Hata T, Sawada Y, Iga T. Comparative pharmacokinetic/pharmacodynamic analysis of proton pump inhibitors omeprazole, lansoprazole and pantoprazole, in humans. Eur J Drug Metab Pharmacokinet . 1998;23(1):19–26.
DOI: http://dx.doi.org/10.1007/BF03189822

63. Sachs G. Improving on PPI-based therapy of GORD. Eur J Gastroenterol Hepatol. 2001;13 Suppl 1:S35-41.

64. Shin JM, Homerin M, Domagala F, Ficheux H, Sachs G. Characterization of the inhibitory activity of tenatoprazole on the gastric H+, K+-ATPase in vitro and in vivo. Biochemical pharmacology. 2006;71(6):837–49.

65. Sachs G. Physiology of the parietal cell and therapeutic implications. Pharmacotherapy. 2003;23(10P2):18-23.
DOI: http://dx.doi.org/10.1592/phco.23.13.68s.31931

66. Hatlebakk JG, Berstad A. Pharmacokinetic optimisation in the treatment of gastrooesophageal reflux disease. Clinical pharmacokinetics. 1996;31:386–406.

67. Hassan-Alin M, Andersson T, Niazi M, Röhss K. A pharmacokinetic study comparing single and repeated oral doses of 20 mg and 40 mg omeprazole and its two optical isomers, S-omeprazole (esomeprazole) and R-omeprazole, in healthy subjects. Eur J Clin Pharmacol. 2005;60(11):779–84.
DOI: http://dx.doi.org/10.1007/s00228-004-0841-1.

68. Mansfield P, Henry D, Tonkin A. Single-enantiomer drugs: elegant science, disappointing effects: Elegant science, disappointing effects. Clin Pharmacokinet. 2004;43(5):287–90.
DOI: http://dx.doi.org/10.2165/00003088-200443050-00002.

69. Domagala F, Ficheux H. Pharmacokinetics of tenatoprazole, a novel proton pump inhibitor, in healthy male Caucasian volunteers. Gastroenterology. 2003;124(4):A231.
DOI: http://dx.doi.org/10.1016/s0016-5085(03)81159-9

70. Hunt RH, Armstrong D, James C, Chowdhury SK, Yuan Y, Fiorentini P, et al. Effect on intragastric pH of a PPI with a prolonged plasma half-life: comparison between tenatoprazole and esomeprazole on the duration of acid suppression in healthy male volunteers. Am J Gastroenterol. 2005;100(9):1949–56.
DOI: http://dx.doi.org/10.1111/j.1572-0241.2005.41956.x